Conversation with The Cancer Letter

Conversation with The Cancer Letter

FDA: For Hospitals that Significantly Violated Federal Adverse Event Reporting Requirement, No Additional Action Necessary
Conversation with The Cancer LetterFree

FDA: For Hospitals that Significantly Violated Federal Adverse Event Reporting Requirement, No Additional Action Necessary

In a 17-institution inspection sparked by reports of patient harm and death resulting from power morcellators and contaminated duodenoscopes, FDA found that nearly all hospitals surveyed either failed to report adverse events or didn't have proper reporting and documentation procedures in place.
By Matthew Bin Han Ong
Perspectives on Clinical Development of PD-1 Drugs
Conversation with The Cancer LetterFree

Perspectives on Clinical Development of PD-1 Drugs

Question 1: Is there a reason to believe that these drugs are different from each other?Abrams & Sharon: From our estimate, there are more than 700 trials on ClinicalTrials.gov, with the bulk of those trials (approximately 700) involving agents from the five leading PD-1/PD-L1 companies (Merck, BMS, AZ, Genentech, and EMD Serono/Pfizer). There are obviously some subtle differences in terms of agents that target PD-1 versus PD-L1, but by and large, if there is efficacy with one agent seen, then we have generally seen a similar range of efficacy with the other agents.